AtriCure (ATRC) Tops Q4 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts ATRC Hot Sheet
Price: $60.41 +0.89%
Financial Fact:
Basic and diluted net loss per share: -0.21
Today's EPS Names:
WMK, FACO, SEB, More
Financial Fact:
Basic and diluted net loss per share: -0.21
Today's EPS Names:
WMK, FACO, SEB, More
Join SI Premium – FREE
AtriCure (NASDAQ: ATRC) reported Q4 EPS of ($0.09), $0.09 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $88 million versus the consensus estimate of $87.77 million.
GUIDANCE:
AtriCure sees FY2023 revenue of $380-387 million, versus the consensus of $381.7 million.
For earnings history and earnings-related data on AtriCure (ATRC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AtriCure (ATRC) Tops Q3 EPS by 21c; Offers Guidance
- First Tracks Biotherapeutics, Inc. (TRAX) Misses Q3 EPS by 88c
- Ashland (ASH) Misses Q4 EPS by 16c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
